Medicare AdvantageCoverageLow impact
MA11.007b, Islet Cell Transplantation, including use of Donislecel-jujn (Lantidra)
Independence Blue Cross·Endocrinology, General Surgery·Medical Policy
Effective date
Apr 1, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA11.007b covering Islet Cell Transplantation and Donislecel-jujn (Lantidra) has been reissued with an effective date of April 1, 2026. This policy update affects coverage and billing requirements for islet cell transplantation procedures under Medicare Advantage plans.
Action Required
By April 1, 2026: Review updated Medicare Advantage policy MA11.007b for islet cell transplantation coverage criteria and billing requirements. Billing team should access the full policy details at the provided URL to understand any changes to prior authorization, documentation, or coverage requirements for these specialized procedures.